Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Buschmann

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Chemmedchem|December 11, 2012
N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicitySeong Jun Park, Hannah Baars, Stefanie Mersmann, et al.
Antiviral Research|April 18, 2025
The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: Pharmacophore-based identification of NEC-specific inhibitorsJulia Tillmanns, Verena Battisti, Jintawee Kicuntod, et al.
British Journal of Pharmacology|June 20, 2006
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese ratsAngels Fisas, Xavier Codony, Gonzalo Romero, et al.
Expert Opinion on Pharmacotherapy|June 16, 2012
Mechanistic and functional differentiation of tapentadol and tramadolRobert B Raffa, Helmut Buschmann, Thomas Christoph, et al.
International Immunopharmacology|August 17, 2010
Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitorsMiguel A Iñiguez, Carmen Punzón, Cristina Cacheiro-Llaguno, et al.
Journal of Medicinal Chemistry|March 18, 2005
Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesityAntoni Torrens, Josep Mas, Adriana Port, et al.
European Journal of Pharmacology|May 2, 2013
Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effectsAlba Vidal-Torres, Beatriz de la Puente, Maria Rocasalbas, et al.
Journal of Medicinal Chemistry|July 13, 2012
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)José Luis Díaz, Rosa Cuberes, Joana Berrocal, et al.
Journal of Medicinal Chemistry|March 18, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligandsJörg Holenz, Ramon Mercè, José Luis Díaz, et al.
Chemmedchem|August 8, 2006
A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligandsJordi Corbera, David Vaño, Daniel Martínez, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Chemmedchem|December 11, 2012
N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicitySeong Jun Park, Hannah Baars, Stefanie Mersmann, et al.
Antiviral Research|April 18, 2025
The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: Pharmacophore-based identification of NEC-specific inhibitorsJulia Tillmanns, Verena Battisti, Jintawee Kicuntod, et al.
British Journal of Pharmacology|June 20, 2006
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese ratsAngels Fisas, Xavier Codony, Gonzalo Romero, et al.
Expert Opinion on Pharmacotherapy|June 16, 2012
Mechanistic and functional differentiation of tapentadol and tramadolRobert B Raffa, Helmut Buschmann, Thomas Christoph, et al.
International Immunopharmacology|August 17, 2010
Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitorsMiguel A Iñiguez, Carmen Punzón, Cristina Cacheiro-Llaguno, et al.
Journal of Medicinal Chemistry|March 18, 2005
Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesityAntoni Torrens, Josep Mas, Adriana Port, et al.
European Journal of Pharmacology|May 2, 2013
Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effectsAlba Vidal-Torres, Beatriz de la Puente, Maria Rocasalbas, et al.
Journal of Medicinal Chemistry|July 13, 2012
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)José Luis Díaz, Rosa Cuberes, Joana Berrocal, et al.
Journal of Medicinal Chemistry|March 18, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligandsJörg Holenz, Ramon Mercè, José Luis Díaz, et al.
Chemmedchem|August 8, 2006
A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligandsJordi Corbera, David Vaño, Daniel Martínez, et al.
Pageof 5